Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Income from Continuing Operations: 2014-2024

Historic Income from Continuing Operations for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.4 million.

  • Cartesian Therapeutics' Income from Continuing Operations fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • As of FY2024, Cartesian Therapeutics' Income from Continuing Operations stood at -$77.4 million, which was up 64.76% from -$219.7 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Income from Continuing Operations ranged from a high of $35.4 million in FY2022 and a low of -$219.7 million during FY2023.
  • For the 3-year period, Cartesian Therapeutics' Income from Continuing Operations averaged around -$87.3 million, with its median value being -$77.4 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first surged by 237.73% in 2022, then plummeted by 721.02% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Income from Continuing Operations stood at -$68.9 million in 2020, then spiked by 62.71% to -$25.7 million in 2021, then skyrocketed by 237.73% to $35.4 million in 2022, then crashed by 721.02% to -$219.7 million in 2023, then surged by 64.76% to -$77.4 million in 2024.